SCHEMBL17087424

SCHEMBL17087424

CCn1c(CN(C)Cc2ccc(/C=C/C(=O)NO)cc2)nc2c(N3CCOCC3)nc(Cl)nc21

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ HDAC1 Q13547 14/20 0.47
▸ PIK3R1 P27986 2/20 0.45
▸ PIK3CA P42336 2/20 0.45
▸ HDAC3 O15379 3/20 0.40
▸ HDAC6 Q9UBN7 3/20 0.40
▸ CCNA2 P20248 1/20 0.40
▸ CDK2 P24941 1/20 0.40
▸ HDAC8 Q9BY41 3/20 0.39
▸ HDAC4 P56524 2/20 0.39
▸ HDAC2 Q92769 2/20 0.39
▸ HDAC10 Q969S8 2/20 0.39
▸ HDAC5 Q9UQL6 2/20 0.39
▸ MAPT P10636 4/20 0.39
▸ LMNA P02545 3/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ HDAC7 Q8WUI4 1/20 0.37
▸ HDAC11 Q96DB2 1/20 0.37
▸ HDAC9 Q9UKV0 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18490826 1.00 HDAC1 (0.47) HDAC1PIK3R1PIK3CAHDAC3HDAC6
SCHEMBL18505785 0.95 HDAC1 (0.45) HDAC1PIK3R1PIK3CACCNA2CDK2
SCHEMBL17078420 0.92 HDAC1 (0.46) HDAC1PIK3R1PIK3CAHDAC3HDAC6
SCHEMBL17078423 0.92 HDAC1 (0.46) HDAC1PIK3R1PIK3CAHDAC3HDAC6
SCHEMBL18505794 0.91 HDAC1 (0.44) HDAC1PIK3R1PIK3CAHDAC3HDAC6
SCHEMBL18490837 0.86 HDAC1 (0.56) HDAC1PIK3R1PIK3CAHDAC3HDAC6
SCHEMBL17087341 0.86 HDAC1 (0.56) HDAC1PIK3R1PIK3CAHDAC3HDAC6
SCHEMBL17087419 0.85 HDAC1 (0.65) HDAC1PIK3R1PIK3CAHDAC3HDAC6
SCHEMBL18490833 0.85 HDAC1 (0.65) HDAC1PIK3R1PIK3CAHDAC3HDAC6
SCHEMBL18518254 0.84 HDAC1 (0.57) HDAC1PIK3R1PIK3CAHDAC3HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180265512-A1 FUSED PYRIMIDINE-BASED HYDROXAMATE DERIVATIVES AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2018-09-20 — — US disclosed
US-9957270-B2 Fused pyrimidine-based hydroxamate derivatives AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2018-05-01 — — US disclosed
US-9957270-B2 Fused pyrimidine-based hydroxamate derivatives AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2018-05-01 — — US disclosed
US-9957270-B2 Fused pyrimidine-based hydroxamate derivatives AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2018-05-01 — — US disclosed
US-20170044162-A1 Fused Pyrimidine-Based Hydroxamate Derivatives AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2017-02-16 — — US disclosed
US-20170044162-A1 Fused Pyrimidine-Based Hydroxamate Derivatives AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2017-02-16 — — US disclosed
US-20170044162-A1 Fused Pyrimidine-Based Hydroxamate Derivatives AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2017-02-16 — — US disclosed
WO-2015137887-A1 FUSED PYRIMIDINE-BASED HYDROXAMATE DERIVATIVES AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2015-09-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170044162-A1 Fused Pyrimidine-Based Hydroxamate Derivatives HDAC1, HDAC2, HDAC5 HDAC1 1/4885PIK3R1 934/4885PIK3CA 301/4885
US-20180265512-A1 FUSED PYRIMIDINE-BASED HYDROXAMATE DERIVATIVES HDAC1, HDAC5, HDAC2 HDAC1 1/4885PIK3R1 1108/4885PIK3CA 321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback